NTRK3

(redirected from ETV6-NTRK3 fusion)

NTRK3

A gene on chromosome 15q25 that encodes TrkC receptor, a tyrosine-protein kinase receptor activated by neurotrophin-3 (NT-3) and is found on proprioceptive sensory neurons; its substrates include SHC1, PI-3 kinase and PLCG1.
Mentioned in ?
References in periodicals archive ?
The resultant ETV6-NTRK3 fusion product is a constitutively active chimeric tyrosine kinase and has transformation capacity in the mammary epithelial and myoepithelial cells.
3,8) It should be mentioned that in salivary gland tumors, the ETV6-NTRK3 fusion is unique to MASC.
Mammary analogue secretory carcinoma of salivary glands: molecular analysis of 25 ETV6 gene rearranged tumors with lack of detection of classical ETV6-NTRK3 fusion transcript by standard RT-PCR: report of 4 cases harboring ETV6-X gene fusion.
In addition, and most importantly, it harbors a t(12;15)(p13;q25) translocation, resulting in ETV6-NTRK3 fusion product.
It will stain positive for vimentin, and genetic analysis will show a t(12;15) (p13;q25) translocation with a corresponding ETV6-NTRK3 fusion gene, diagnostic for IF.
3) This t(12; 15)(p13; q25) translocation results in the generation of an ETV6-NTRK3 fusion transcript that is specific to MASC among other salivary gland tumors.
Secretory breast carcinoma with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrum.
21, 45) The ETV6-NTRK3 fusion gene encodes a chimeric tyrosine kinase; the latter activates both Rasmitogen-activated protein kinase pathway and phosphatidylinositol-3-kinase-ATK pathway.
25,53) In difficult cases, molecular testing for ETV6-NTRK3 fusion would be helpful for the differential diagnosis.
25) Although it is not always present, the ETV6-NTRK3 fusion gene is specific for secretory carcinoma and has not been detected in any other types of breast carcinomas.
A fluorescence in situ hybridization study of ETV6-NTRK3 fusion gene in secretory breast carcinoma.
2) Other renal tumors of childhood have been associated with recurring genetic abnormalities: deletion or mutations of WT1 and p53 in some Wilms tumors, t (12;15) creating the ETV6-NTRK3 fusion gene in congenital mesoblastic nephroma, and INI1 deletions or mutations in malignant rhabdoid tumors.